![]() Subjects receiving allowed concomitant medications need to be on stable therapy for 28 days prior to the Baseline visit, with the exception of ursodeoxycholic acid (UDCA), which should be stable for at least 6 weeks prior to the Baseline visit.Be able to understand and sign a written informed consent form (ICF).Have a serum ALP ≥1.5 × upper limit of normal (ULN).Subjects who are on treatment are allowed, provided they are stable for 3 months if taking: In addition, subjects may only enter the study with a Partial Mayo Score of 0-4, inclusively. ![]() If a subject has IBD, documented evidence of IBD must have been evident by prior endoscopy or in previous medical records for ≥6 months. If subjects have Inflammatory Bowel Disease (IBD) they will be eligible to participate.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |